JP2010524893A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524893A5
JP2010524893A5 JP2010503510A JP2010503510A JP2010524893A5 JP 2010524893 A5 JP2010524893 A5 JP 2010524893A5 JP 2010503510 A JP2010503510 A JP 2010503510A JP 2010503510 A JP2010503510 A JP 2010503510A JP 2010524893 A5 JP2010524893 A5 JP 2010524893A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
nitrovinyl
imidazol
propylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010503510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524893A (ja
JP5675340B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/054710 external-priority patent/WO2008128981A1/en
Publication of JP2010524893A publication Critical patent/JP2010524893A/ja
Publication of JP2010524893A5 publication Critical patent/JP2010524893A5/ja
Application granted granted Critical
Publication of JP5675340B2 publication Critical patent/JP5675340B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010503510A 2007-04-18 2008-04-18 新規阻害剤 Expired - Fee Related JP5675340B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91253707P 2007-04-18 2007-04-18
US60/912,537 2007-04-18
PCT/EP2008/054710 WO2008128981A1 (en) 2007-04-18 2008-04-18 Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors

Publications (3)

Publication Number Publication Date
JP2010524893A JP2010524893A (ja) 2010-07-22
JP2010524893A5 true JP2010524893A5 (https=) 2011-05-19
JP5675340B2 JP5675340B2 (ja) 2015-02-25

Family

ID=39639570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503510A Expired - Fee Related JP5675340B2 (ja) 2007-04-18 2008-04-18 新規阻害剤

Country Status (6)

Country Link
US (1) US8772508B2 (https=)
EP (1) EP2142513B1 (https=)
JP (1) JP5675340B2 (https=)
DK (1) DK2142513T3 (https=)
ES (1) ES2468551T3 (https=)
WO (1) WO2008128981A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
CA2696934A1 (en) * 2007-09-12 2010-02-16 Probiodrug Ag Transgenic mice
NZ586665A (en) * 2008-01-14 2011-12-22 Probiodrug Ag MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE (Qpct)
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011076854A1 (en) 2009-12-22 2011-06-30 Probiodrug Ag CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
MY161487A (en) 2010-02-08 2017-04-14 Coca Cola Co Solubility enhanced terpene glycoside(s)
EP2537029A1 (en) 2010-02-18 2012-12-26 Probiodrug AG Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
BR112013023211B1 (pt) 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2016097305A1 (en) 2014-12-19 2016-06-23 Probiodrug Ag Novel method for the detection of pglu-abeta peptides
EP3362082A1 (en) * 2015-10-16 2018-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ, インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
WO2020123449A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277485A (en) * 1973-05-17 1981-07-07 Smith Kline & French Laboratories Limited Oxazole or isoxazole alkylamino ethylene compounds as inhibitors of H-2 histamine receptors
DE3044566A1 (de) * 1980-11-26 1982-07-15 Basf Ag, 6700 Ludwigshafen N-substituierte imidazol-derivate, ihre herstellung, diese enthaltende arzneimittel und ihre verwendung
AU2001241194A1 (en) 2000-03-21 2001-10-03 Ishihara Sangyo Kaisha Ltd. Nitroethenamine derivatives or salts thereof and pharmaceutical compositions containing the derivatives or the salts
US6948038B2 (en) 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR20110059664A (ko) 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
JP4806628B2 (ja) * 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
BRPI0718507A2 (pt) 2006-09-21 2013-11-12 Probiodrug Ag Genes relacionados à glutaminil ciclase
US8420684B2 (en) 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP2010516235A (ja) 2007-01-19 2010-05-20 プロビオドルグ エージー アルツハイマー病及び他のqpct関連障害の治療のためのインビボスクリーニングモデル
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors

Similar Documents

Publication Publication Date Title
JP2010524893A5 (https=)
JP2010524898A5 (https=)
JP2010524895A5 (https=)
JP2010524899A5 (https=)
JP2010524897A5 (https=)
JP2010524896A5 (https=)
JP2010509284A5 (https=)
JP2010511013A5 (https=)
JP2013504544A5 (https=)
JP2010509286A5 (https=)
JP2010509285A5 (https=)
JP2010520869A5 (https=)
JP2013521325A5 (https=)
JP2020512373A5 (https=)
JP2013521260A5 (https=)
JP2012502006A5 (https=)
JP5191497B2 (ja) S1p受容体調節化合物およびその使用
IL307911A (en) New inhibitors
JP2022506887A5 (https=)
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
JP2014508184A5 (https=)
AU782191B2 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
JP2013525334A5 (https=)
KR20130042590A (ko) 기질 메탈로프로테나제 저해제
US11479550B2 (en) EP4 antagonist